Biontech Stock – Why BioNTech Stock Is Jumping Today
BioNTech reported quarterly revenue of 345.4 million euros, a huge increase from the 28 million euros it brought in during the prior-year period. It also achieved profitability for the first time as a publicly traded company.
BioNTech‘s Q4 results included only a few weeks of sales of BNT162b2, though. The vaccine won its first authorization in the UK. on Dec. 2. Over the next few weeks, BioNTech and Pfizer secured additional regulatory authorizations in the U.S. and in the European Union.
Investors might need to get used to seeing great quarterly results that send this biotech stock higher. BioNTech expects to generate revenue of around 9.8 billion euros from its current supply agreements. However, the company thinks that even more supply deals are coming, which will further boost its revenue.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Fintech Zoom premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.